{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:57Z","timestamp":1780898397950,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy. Tagraxofusp, a CD123-directed cytotoxin, was approved based on phase I\/II data, and subsequent studies have expanded evidence across trial and real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Scopus, and Google Scholar for English-language human studies through January 25, 2026. We included adults (\u226518 years) with BPDCN treated with tagraxofusp who reported efficacy and\/or safety outcomes; abstracts without extractable data, narrative reviews, expert guidance, pediatric-only studies, and preclinical studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven studies were included, representing 343 unique adult patients treated with tagraxofusp after adjustment for overlapping analyses from the pivotal NCT02113982 trial program. Frontline trials reported overall response rates (ORR) of 71%\u201390% with CR\/CRc rates of 56%\u201372%. Real-world cohorts showed ORR of 65%\u201390% and highlighted superior survival among patients bridged to allogeneic hematopoietic stem cell transplantation (HSCT). Capillary leak syndrome (CLS) was the defining toxicity, with variable incidence across clinical trials and observational cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tagraxofusp demonstrates consistent remission-inducing activity in adults with BPDCN across prospective and real-world settings. Long-term survival appears strongly influenced by successful bridging to HSCT. Evidence remains predominantly non-randomized, underscoring the need for comparative and combination studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1853982","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:34Z","timestamp":1780896994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Bassam","family":"Muthanna","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Missouri-Columbia","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadhila Abbas","family":"Manthiri","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Haj Saleh","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research (NCCCR)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research (NCCCR)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2015.145","article-title":"Neoplasms derived from plasmacytoid dendritic cells","volume":"29","author":"Facchetti","year":"2016","journal-title":"Mod Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","author":"Kharfan-Dabaja","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the EBMT","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02456-3","article-title":"Allogeneic hematopoietic stem cell transplantation in blastic plasmacytoid dendritic cell neoplasm: timing and patient selection","volume":"60","author":"Angelucci","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for\u00a0patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2475338","article-title":"Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial","volume":"66","author":"Pemmaraju","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70243","article-title":"Post hoc analysis of tagraxofusp in first-line blastic plasmacytoid dendritic cell neoplasm","volume":"132","author":"Konopleva","year":"2026","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06221-4","article-title":"Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm","volume":"104","author":"Lee","year":"2025","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06493-w","article-title":"Durable outcomes with manageable safety\u00a0leading to prolonged survival with tagraxofusp for treatment-na\u00efve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program","volume":"104","author":"Herling","year":"2025","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2553862","article-title":"Tagraxofusp in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm: real-world experience","volume":"66","author":"Angelucci","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2305288","article-title":"Treatment of patients with blastic plasmacytoid dendritic cell neoplasm: focus on tagraxofusp and clinical considerations","volume":"65","author":"Pemmaraju","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2557505","article-title":"Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Lane","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172953","article-title":"Evaluation of treatment outcomes in adults with blastic plasmacytoid dendritic cell neoplasm: a systematic review and meta-analysis","volume":"142","author":"Sandhu","year":"2023","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological\u00a0index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"Anz J Surg"},{"key":"B21","volume-title":"The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":""},{"key":"B22","article-title":"Chapter 7: systematic reviews of etiology and risk","volume-title":"JBI manual for evidence synthesis","author":"Moola","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04151-5","article-title":"Phase I\/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm","volume":"123","author":"Yokota","year":"2026","journal-title":"Int J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280843","article-title":"Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction","volume":"107","author":"Vangala","year":"2022","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011817","article-title":"Central\u00a0nervous system involvement in blastic plasmacytoid dendritic cell neoplasm: two cases treated with tagraxofusp","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100486","article-title":"Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience","volume":"22","author":"Andanamala","year":"2024","journal-title":"Leuk Res Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.09.009","article-title":"Capillary leak syndrome following\u00a0tagraxofusp administration in a patient with blastic plasmacytoid dendritic cell neoplasm","volume":"3","author":"Mouhayar","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-021-00479-z","article-title":"Successful treatment of blastic plasmacytoid dendritic\u00a0cell neoplasm with tagraxofusp without hematopoietic stem cell transplantation","volume":"38","author":"Gulati","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"23247096231158506","DOI":"10.36401\/JIPO-23-43","article-title":"Complete remission with tagraxofusp in treatment-na\u00efve blastic plasmacytoid dendritic cell neoplasm","volume":"11","author":"Dhakal","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220951850","article-title":"Tagraxofusp in treatment-na\u00efve blastic plasmacytoid dendritic cell neoplasm: a case report","volume":"27","author":"Samhouri","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.541","article-title":"Capillary leak syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp","volume":"12","author":"Sibai","year":"2022","journal-title":"J Hematol Oncol Pharm"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03777-2","article-title":"Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report","volume":"148","author":"Koerber","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1384172","article-title":"Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports","volume":"14","author":"Faustmann","year":"2024","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.57187\/s.3885","article-title":"Blastic plasmacytoid dendritic cell neoplasm: case series and literature review","volume":"155","author":"Meier-Lienhard","year":"2025","journal-title":"Swiss Med Wkly"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.010","article-title":"Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"24","author":"Pemmaraju","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.008","article-title":"Successful salvage therapy with tagraxofusp in post-transplant relapse of blastic plasmacytoid dendritic cell neoplasm","volume":"21","author":"Wang","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2025.100518","article-title":"Complete remission with tagraxofusp in treatment-na\u00efve blastic plasmacytoid dendritic cell neoplasm without capillary leak syndrome","volume":"23","author":"Basir","year":"2025","journal-title":"Leuk Res Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13399","article-title":"Successful treatment of cutaneous blastic plasmacytoid dendritic cell neoplasm with tagraxofusp","volume":"62","author":"Massone","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06794-8","article-title":"Skin-limited response to tagraxofusp in blastic plasmacytoid dendritic cell neoplasm","volume":"105","author":"Brummer","year":"2026","journal-title":"Ann Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93784","article-title":"Complete remission with tagraxofusp in treatment-na\u00efve blastic plasmacytoid dendritic cell neoplasm","volume":"17","author":"Staessens","year":"2025","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:35Z","timestamp":1780896995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1853982"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1853982","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1853982"}}